StrideBio’s genetic construct design expertise and in-house manufacturing capabilities provide flexibility to scale and support clinical development of AAV-based genetic medicines.
Genetic Construct Design
StrideBio’s genetic construct design expertise enables us to have flexibility across modalities beyond gene replacement when designing and developing product candidates for multiple therapeutic targets. We are initially focused on developing products to treat rare, monogenic diseases.
Our wholly owned proprietary cell-line and manufacturing process and on-site manufacturing capability are optimized for the novel capsids resulting from our STRIVE platform and gives us the flexibility to scale and support clinical development of genetic therapies.
- Process Development infrastructure includes 1000L single-use bioreactor
- 5,000-square-foot GMP clean suite to be completed and online in 2020
- 24,000-square-foot facility in RTP, including office, labs and in-house manufacturing suites